Form 4: Guardant Health Director Meghan Joyce Reports Stock Unit Vesting

Director Meghan Joyce of Guardant Health, Inc. reported the vesting of 66 restricted stock units on January 4, 2025.

Summary

• Meghan Joyce, a director at Guardant Health, Inc., reported a transaction on January 4, 2025.
• The transaction involved the vesting of 66 restricted stock units.
• These units converted into 66 shares of common stock.
• The price per unit was $0, as it was a vesting event, not a purchase.
• Following this transaction, Ms. Joyce directly owns 7,681 shares of common stock and 465 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine filing of an insider transaction, which is neither positive nor negative for the company's overall performance. It's a standard part of compensation.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It reflects the standard practice of equity compensation for directors.

Comparison to Industry Standards

• The vesting of restricted stock units is a common form of compensation for directors and executives in publicly traded companies, particularly in the technology and healthcare sectors.
• Companies like Illumina, Exact Sciences, and Myriad Genetics also use similar equity-based compensation plans.
• The vesting schedule described, with an initial 25% vesting followed by monthly installments, is a typical structure for these types of awards.

Stakeholder Impact

• The vesting of stock units has a minor dilutive effect on existing shareholders, but it is a standard practice for incentivizing directors.
• The transaction does not have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Guardant Health, stock units, vesting, director, insider trading, equity compensation, Form 4